Jun 16, 2016 by Brian Orelli, PhDMerck & Co., Inc. Wins This Round of the Immunotherapy Lung-Cancer BattleThere are still a few more rounds to go.
Jun 14, 2016 by Brian Orelli, PhDWhy ImmunoGen, Inc. Noted a Lower Price TodayA capital raise could lead to shareholder dilution.
Jun 10, 2016 by Brian Orelli, PhDWhy Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today Positive data sends the two biotechs in opposite directions.
Jun 9, 2016 by Brian Orelli, PhDWhy Agios Pharmaceuticals Inc. Presented Lower TodayPotential safety issues with one of the biotech's pipeline drugs worry investors.
Jun 8, 2016 by Brian Orelli, PhDExelixis, Inc. Setting New Standard of CareLook at what Cabometyx did -- again.
Jun 7, 2016 by Brian Orelli, PhDWhy Biogen Inc's Shares Couldn't Find SYNERGY TodayPipeline prospect opicinumab failed a phase 2 clinical trial in multiple sclerosis.
Jun 6, 2016 by Brian Orelli, PhDExelixis, Inc. Gets Some ASCO LoveThe biotech had a good showing at the American Society of Clinical Oncology meeting.
Jun 2, 2016 by Brian Orelli, PhDWhy Keryx Biopharmaceuticals Shouldn't Be Up TodayThe devil is in the details.
Jun 1, 2016 by Brian Orelli, PhDFirst Impressions of the New 365 by Whole Foods Market Inc. ConceptA Fool provides a detailed walkthrough of the company's new smaller store format, which debuted in Los Angeles late last month.
May 26, 2016 by Brian Orelli, PhDWhy Alnylam Pharmaceuticals, Inc. Competed Higher TodayOne biotech's bad luck is another biotech's good fortune.
May 26, 2016 by Brian Orelli, PhDWhy Ionis Pharmaceuticals Plummeted TodaySevere platelet declines in two of its drugs rock the stock.
May 24, 2016 by Brian Orelli, PhDBetter Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals Inc.A battle of the RNA-targeting drugmakers.
May 12, 2016 by Brian Orelli, PhDbluebird bio Inc: Catnapping in CambridgeA sleepy first-quarter update from the biotech.
May 12, 2016 by Brian Orelli, PhDEmergent BioSolutions Inc in TransitionThe biodefense company prepares for higher revenue and lower costs.
May 12, 2016 by Brian Orelli, PhDExelixis, Inc. Prepares for BlastoffThe biotech launches Cabometyx for kidney cancer.
May 11, 2016 by Brian Orelli, PhDWhy Endo International plc Investigated a Lower PriceThe U.S. Attorney’s Office requests information from the drugmaker's contracts with pharmacy benefit managers.
May 10, 2016 by Brian Orelli, PhDGenomic Health, Inc. Earnings: Waiting for (More) ReimbursementVolume growth from the cancer-test maker was outstanding, and while there's work to go on reimbursement, revenue increased 19% year over year.
May 10, 2016 by Brian Orelli, PhDIonis Pharmaceuticals Inc Is Burning Partners' Cash (Thank Goodness There's Lots of It)Even with a drug on the market, it's all about the pipeline for this biotech.
May 9, 2016 by Brian Orelli, PhDWhy Horizon Pharma PLC Earned a Higher Stock PriceThe spec pharma meets its expectations.
![hznp-corp-hq_large1_large[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F205410%2Fhznp-corp-hq_large1_large1.jpg&w=384&op=resize)
![cldx-logo-on-jacket_large[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F205378%2Fcldx-logo-on-jacket_large1.jpg&w=384&op=resize){kind=logo}